We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Differential Effects of Bevacizumab, Ranibizumab, and Aflibercept on the Viability and Wound Healing of Corneal Epithelial Cells.
- Authors
Kang, Seungbum; Choi, Hyunsu; Rho, Chang Rae
- Abstract
<bold>Purpose: </bold>This study compared the effects of 3 antivascular endothelial growth factor (VEGF) agents (bevacizumab, ranibizumab, and aflibercept) on corneal epithelial cell viability and wound healing using human corneal epithelial cells (HCECs).<bold>Methods: </bold>To determine the cytotoxic effects of anti-VEGF agents on HCECs, HCEC viability was determined at various concentrations of these agents. An in vitro migration assay was used to investigate the migration of HCECs treated with 3 anti-VEGF agents. The protein level of extracellular signal-regulated kinase was used to evaluate the effect of anti-VEGF treatment on cell proliferation. The protein levels of p38 mitogen-activated protein kinase (MAPK) were analyzed by Western blotting to investigate cell migration.<bold>Results: </bold>After 24 or 48 h of exposure, aflibercept treatment showed no apparent effect on cell viability; however, bevacizumab and ranibizumab treatment decreased cell viability at high concentrations (1 and 2 mg/mL). A migration assay showed that HCEC migration was different among the 3 anti-VEGF treatment groups. Bevacizumab significantly delayed HCEC migration. Western blotting showed that bevacizumab treatment decreased the expression levels of phosphorylated p38 MAPK.<bold>Conclusions: </bold>Bevacizumab, the most widely used and investigated anti-VEGF agent, decreased epithelial cell migration and viability. Anti-VEGF agents other than bevacizumab might therefore be better for treating corneal neovascularization complicated with epithelial defects.
- Subjects
BEVACIZUMAB; RANIBIZUMAB; CORNEA injuries; VASCULAR endothelial growth factors; MITOGEN-activated protein kinases; WESTERN immunoblotting; THERAPEUTICS; VASCULAR endothelial growth factor antagonists; BIOCHEMISTRY; CELL culture; CELL physiology; CELL receptors; DOSE-effect relationship in pharmacology; EPITHELIAL cells; EPITHELIUM; PHENOMENOLOGY; NEOVASCULARIZATION inhibitors; RECOMBINANT proteins; WOUND healing; PHARMACODYNAMICS
- Publication
Journal of Ocular Pharmacology & Therapeutics, 2016, Vol 32, Issue 10, p671
- ISSN
1080-7683
- Publication type
journal article
- DOI
10.1089/jop.2016.0094